Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries

Angiogenesis inhibitors have become standard of care for advanced and/or metastatic renal cell carcinoma (RCC), but data on the impact of adverse events (AEs) and treatment modifications associated with these agents are limited. Medical records were abstracted at 10 tertiary oncology centers in Euro...

Full description

Bibliographic Details
Main Authors: Porta, Camillo, Levy, Antonin, Hawkins, Robert, Castellano, Daniel, Bellmunt, Joaquim, Nathan, Paul, McDermott, Ray, Wagstaff, John, Donnellan, Paul, McCaffrey, John, Vekeman, Francis, Neary, Maureen P, Diaz, Jose, Mehmud, Faisal, Duh, Mei Sheng
Format: Online
Language:English
Published: Blackwell Publishing Ltd 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298378/

Similar Items

Similar Items